Forty-eight chronic male patients with schizophrenia with vitamin D deficiency (≤20 ng/mL= (≤50 nmol/l) were selected and randomly assigned to vitamin D treatment and placebo groups. Subjects were supplemented for 8 weeks with vitamin D (2000 IU/day) or placebo.
Within-group comparison revealed that the vitamin D group had a significant reduction in waist circumference, Positive and Negative Syndrome Scale - total score (PANSS-TS), and glycogen synthase kinase 3 beta (GSK-3β) levels (P = .022, P = <.001 and P = .013, respectively). On the other hand, the placebo group showed a significant increase in the level of fasting serum insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (P = .003 and P = .003). The between-group comparison showed a significant difference in terms of PANSS-TS, GSK-3β, fasting serum insulin (FSI), and HOMA-IR (P = .022, P = .048, P = .013 and P = .014 respectively).
Among vitamin D deficient patients with schizophrenia, vitamin D supplementation may affect GSK-3 β, an important biomarker in schizophrenia and insulin resistance. In addition, vitamin D supplementation in such patients may reduce the disorder\'s symptom severity.
方法:选择48例伴维生素D缺乏(≤20ng/mL=(≤50nmol/l)的精神分裂症慢性男性患者,随机分为维生素D治疗组和安慰剂组。受试者补充维生素D(2000IU/天)和安慰剂8周,分别。
结果:组内比较显示,维生素D组腰围明显减少,阳性和阴性综合征量表-总分(PANSS-TS)和,糖原合成酶激酶3β(GSK-3β)水平(分别为P=.022,P=<.001和P=.013)。另一方面,安慰剂组的空腹血清胰岛素水平和胰岛素抵抗稳态模型评估(HOMA-IR)水平显著升高(P=.003和P=.003).组间比较显示在PANSS-TS方面有显著差异,GSK-3β,空腹血清胰岛素(FSI)和HOMA-IR(分别为P=.022,P=.048,P=.013和P=.014)。
结论:在缺乏维生素D的精神分裂症患者中,补充维生素D可能会影响GSK-3β,精神分裂症和胰岛素抵抗的重要生物标志物。此外,此类患者补充维生素D可能会减轻症状严重程度。